When FluCide exits phase 2/3 trials, a license will be valued at $5 billion for the entire FluCide platform. After approval the total potential market for the entire platform will be in the $25 billion range. Anyone with access to google can research recent license deals and with a calculator confirm the numbers. FluCide will first be administered in critical care settings which will bring a premium of value to shareholders. In 2005, my ICU antibiotic cocktail came to $7500, and I wasn't immune compromised.
News 
Market Data 
Discover 
